Floatz logo

Thalidomide

Waldenstrom's Macroglobulinemia

Steven P. Treon, MD, PhDSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

60 Active assets in the Waldenstrom's Macroglobulinemia cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Fred Hutchinson Cancer Center
Phase 2BBB
Cyclophosphamide
Institute of Hematology & Blood Diseases Hospital, China
Phase 2BBB
Fludarabine
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BBB
PREDNISONE TABLETS
BeOne Medicines
Phase 2BBB
Inno-206
BeOne Medicines
Phase 2BBB

View all 50 →

Same molecule, other indications

Thalidomide is also rated in:

central nervous system neoplasmDormant
BB
Indicative ·
70 / 100
View asset →
plasma cell myelomaDormant
BB
Indicative ·
68 / 100
View asset →
uveal melanomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →